TransCode Therapeutics, Inc. (RNAZ)
Total Valuation
RNAZ has a market cap or net worth of $717,169. The enterprise value is -$6.14 million.
Market Cap | 717,169 |
Enterprise Value | -6.14M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
RNAZ has 6.57 million shares outstanding. The number of shares has increased by 386.56% in one year.
Shares Outstanding | 6.57M |
Shares Change (YoY) | +386.56% |
Shares Change (QoQ) | +139.27% |
Owned by Insiders (%) | 1.35% |
Owned by Institutions (%) | 2.99% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.16 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.13.
Current Ratio | 1.67 |
Quick Ratio | n/a |
Debt / Equity | 0.13 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -821.80% and return on invested capital (ROIC) is -414.87%.
Return on Equity (ROE) | -821.80% |
Return on Assets (ROA) | -267.60% |
Return on Capital (ROIC) | -414.87% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.03M |
Employee Count | 19 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.74% in the last 52 weeks. The beta is -0.38, so RNAZ's price volatility has been lower than the market average.
Beta (1Y) | -0.38 |
52-Week Price Change | -99.74% |
50-Day Moving Average | 0.70 |
200-Day Moving Average | 32.37 |
Relative Strength Index (RSI) | 32.91 |
Average Volume (30 Days) | 659,481 |
Short Selling Information
The latest short interest is 174,746, so 2.66% of the outstanding shares have been sold short.
Short Interest | 174,746 |
Short Previous Month | 101,999 |
Short % of Shares Out | 2.66% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.10 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -20.89M |
Pretax Income | -19.59M |
Net Income | -19.59M |
EBITDA | -19.19M |
EBIT | -19.59M |
Earnings Per Share (EPS) | -$774.80 |
Balance Sheet
The company has $7.45 million in cash and $594,694 in debt, giving a net cash position of $6.86 million or $1.04 per share.
Cash & Cash Equivalents | 7.45M |
Total Debt | 594,694 |
Net Cash | 6.86M |
Net Cash Per Share | $1.04 |
Equity / Book Value | 4.44M |
Book Value Per Share | 0.68 |
Working Capital | 3.78M |
Cash Flow
In the last 12 months, operating cash flow was -$16.43 million and capital expenditures -$63,824, giving a free cash flow of -$16.49 million.
Operating Cash Flow | -16.43M |
Capital Expenditures | -63,824 |
Free Cash Flow | -16.49M |
FCF Per Share | -$208.98 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -386.56% |
Shareholder Yield | -386.56% |
Earnings Yield | -2,731.94% |
FCF Yield | -2,299.96% |
Analyst Forecast
The average price target for RNAZ is $120.00, which is 18,582.86% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $120.00 |
Price Target Difference | 18,582.86% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -74.66% |
Stock Splits
The last stock split was on January 16, 2024. It was a reverse split with a ratio of 1:40.
Last Split Date | Jan 16, 2024 |
Split Type | Reverse |
Split Ratio | 1:40 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |